PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials

PCSK9 inhibitors for anti-inflammation in atherosclerosis: protocol for a systematic review and meta-analysis of randomised controlled trials

Introduction Atherosclerosis is the leading cause of cardiovascular disease (CVD), which is one of the most common causes of morbidity and mortality worldwide. Lipid accumulation and inflammation play a crucial role in the pathogenesis of atherosclerosis. Proprotein convertase subtilisin/kexin type...

Full description

Bibliographic Details
Main Authors: Yan Ma, Wei Li, Xue Wang, Liqun Jiao, Tao Wang, Bin Yang, Jichang Luo, Wenjing Li, Kan Liu, Ran Xu, Wanying Liao, Kaixun Huang
Format: Article
Language:English
Published: BMJ Publishing Group 2022-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/12/11/e062046.full

Similar Items

Similar Items